Indus Biotech Private Limited
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
6
Ending by 2030
Mar 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 22, 2027The maintenance fee for Method for preparation of highly pure asiaticoside composition from Centella asiatica and a method of use thereof (US 9,139,608) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.
- 1 fee due Jun 3, 2027The maintenance fee for Composition of trigofoenoside and flavonoids and methods thereof (US 10,493,088) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
- 1 fee due Jul 26, 2027The maintenance fee for Method of managing urolithiasis and related urological disorders (US 9,241,937) comes due Jul 26, 2027. Unpaid by Jan 26, 2028, it lapses early.
- 2 fees due Aug 9 to 18, 2027 · next Aug 9
Recent changes
- 1 term has ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,149,469 | Pharmaceutical composition and a process thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,669,043 | Synergistic pharmaceutical composition for serotonin reuptake inhibition and process of preparation thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,737,495 | Process for obtaining purified pterostilbene and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,633,229 | Pharmaceutical composition having dopaminergic activity In force · From the USPTO record | In force | From the USPTO record | |
| US 8,288,364 | Botanically derived composition and a process thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,139,608 | Method for preparation of highly pure asiaticoside composition from Centella asiatica and a method of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,956,301 | Complex of garcinol, cyclodextrin and method thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,513,203 | Composition and method thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,563,601 | Method of managing broncho-constrictive condition In force · From the USPTO record | In force | From the USPTO record | |
| US 9,254,269 | Method of managing hypercortisolemia, headache disorders, neuropathic pain and related disorders In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 18: 5 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 no status recorded